Literature DB >> 32491248

Amyloid-beta1-42 induced glutamatergic receptor and transporter expression changes in the mouse hippocampus.

Jason H Y Yeung1, Beatriz Calvo-Flores Guzmán1, Thulani H Palpagama1, Jayarjun Ethiraj1, Ying Zhai1, Warren P Tate2, Katie Peppercorn2, Henry J Waldvogel1, Richard L M Faull1, Andrea Kwakowsky1.   

Abstract

Alzheimer's disease (AD) is the leading type of dementia worldwide. With an increasing burden of an aging population coupled with the lack of any foreseeable cure, AD warrants the current intense research effort on the toxic effects of an increased concentration of beta-amyloid (Aβ) in the brain. Glutamate is the main excitatory brain neurotransmitter and it plays an essential role in the function and health of neurons and neuronal excitability. While previous studies have shown alterations in expression of glutamatergic signaling components in AD, the underlying mechanisms of these changes are not well understood. This is the first comprehensive anatomical study to characterize the subregion- and cell layer-specific long-term effect of Aβ1-42 on the expression of specific glutamate receptors and transporters in the mouse hippocampus, using immunohistochemistry with confocal microscopy. Outcomes are examined 30 days after Aβ1-42 stereotactic injection in aged male C57BL/6 mice. We report significant decreases in density of the glutamate receptor subunit GluA1 and the vesicular glutamate transporter (VGluT) 1 in the conus ammonis 1 region of the hippocampus in the Aβ1-42 injected mice compared with artificial cerebrospinal fluid injected and naïve controls, notably in the stratum oriens and stratum radiatum. GluA1 subunit density also decreased within the dentate gyrus dorsal stratum moleculare in Aβ1-42 injected mice compared with artificial cerebrospinal fluid injected controls. These changes are consistent with findings previously reported in the human AD hippocampus. By contrast, glutamate receptor subunits GluA2, GluN1, GluN2A, and VGluT2 showed no changes in expression. These findings indicate that Aβ1-42 induces brain region and layer specific expression changes of the glutamatergic receptors and transporters, suggesting complex and spatial vulnerability of this pathway during development of AD neuropathology. Read the Editorial Highlight for this article on page 7. Cover Image for this issue: https://doi.org/10.1111/jnc.14763.
© 2020 International Society for Neurochemistry.

Entities:  

Keywords:  Alzheimer's disease; amyloid beta; glutamate receptor; glutamate transporter; hippocampus

Mesh:

Substances:

Year:  2020        PMID: 32491248     DOI: 10.1111/jnc.15099

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  A novel bio-inspired strategy to prevent amyloidogenesis and synaptic damage in Alzheimer's disease.

Authors:  Marcella Catania; Laura Colombo; Stefano Sorrentino; Alfredo Cagnotto; Jacopo Lucchetti; Maria Chiara Barbagallo; Ilaria Vannetiello; Elena Rita Vecchi; Monica Favagrossa; Massimo Costanza; Giorgio Giaccone; Mario Salmona; Fabrizio Tagliavini; Giuseppe Di Fede
Journal:  Mol Psychiatry       Date:  2022-08-26       Impact factor: 13.437

2.  The effects of amyloid-beta on hippocampal glutamatergic receptor and transporter expression.

Authors:  Andrea Kwakowsky; Henry J Waldvogel; Richard Lm Faull
Journal:  Neural Regen Res       Date:  2021-07       Impact factor: 5.135

3.  Beta-Amyloid (Aβ1-42) Increases the Expression of NKCC1 in the Mouse Hippocampus.

Authors:  Patricia Lam; Chitra Vinnakota; Beatriz Calvo-Flores Guzmán; Julia Newland; Katie Peppercorn; Warren P Tate; Henry J Waldvogel; Richard L M Faull; Andrea Kwakowsky
Journal:  Molecules       Date:  2022-04-10       Impact factor: 4.927

4.  iGluR expression in the hippocampal formation, entorhinal cortex, and superior temporal gyrus in Alzheimer's disease.

Authors:  Jason H Y Yeung; Henry J Waldvogel; Richard L M Faull; Andrea Kwakowsky
Journal:  Neural Regen Res       Date:  2022-10       Impact factor: 6.058

5.  Blood neuroexosomal excitatory amino acid transporter-2 is associated with cognitive decline in Parkinson's disease with RBD.

Authors:  Bing Leng; Hairong Sun; Mengfan Li; Junwu Zhao; Xiaoxiao Liu; Ran Yao; Tengqun Shen; Zhenguang Li; Jinbiao Zhang
Journal:  Front Aging Neurosci       Date:  2022-08-23       Impact factor: 5.702

6.  The effect of age and sex on the expression of GABA signaling components in the human hippocampus and entorhinal cortex.

Authors:  Jayarjun Ethiraj; Thulani Hansika Palpagama; Clinton Turner; Bert van der Werf; Henry John Waldvogel; Richard Lewis Maxwell Faull; Andrea Kwakowsky
Journal:  Sci Rep       Date:  2021-11-02       Impact factor: 4.379

7.  TRPV1-Mediated Microglial Autophagy Attenuates Alzheimer's Disease-Associated Pathology and Cognitive Decline.

Authors:  Chenfei Wang; Wei Huang; Jia Lu; Hongzhuan Chen; Zhihua Yu
Journal:  Front Pharmacol       Date:  2022-01-18       Impact factor: 5.810

8.  Glutamatergic receptor expression changes in the Alzheimer's disease hippocampus and entorhinal cortex.

Authors:  Jason H Y Yeung; Joshua L Walby; Thulani H Palpagama; Clinton Turner; Henry J Waldvogel; Richard L M Faull; Andrea Kwakowsky
Journal:  Brain Pathol       Date:  2021-07-16       Impact factor: 6.508

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.